
    
      32 adult healthy subjects with 4 dose groups will be enrolled in the study, including two
      subjects in the lowest dose group, all of whom received the SHR-1209 without placebo control.
      The other three groups have 10 subjects in each group, 8 administered SHR-1209 and 2
      administered placebo. The primary endpoint is the Safety and Tolerability : adverse events,
      vital signs, physical examination, laboratory examination, 12 lead electrocardiogram,
      injection site reactions, etc.
    
  